Trial Profile

A Randomised, Double-blind, Parallel Group, Multicentre Study to Compare the Pharmacokinetics, Pharmacodynamics, Immunogenicity, Safety, and Efficacy of JHL1101 versus EU sourced MabThera in Anti TNF Inadequate Responder Patients with Moderate to Severe RA on Background MTX Therapy

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 29 Mar 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

06 Jan 2020 Status changed from recruiting to discontinued.
12 Jul 2018 Planned primary completion date changed from 30 Jun 2018 to 31 Aug 2018.
29 Mar 2017 Status changed from not yet recruiting to recruiting, according to a JHL Biotech media release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com